<DOC>
	<DOC>NCT00952588</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.</brief_summary>
	<brief_title>Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Provision of written informed consent Newly diagnosed male or female patients aged 60 and over De Novo or Secondary AML Not eligible for intensive induction with anthracyclinebased combination chemotherapy as a result of at least one of the following:Age â‰¥75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status &gt;2; Organ dysfunction arising from significant comorbidities not directly linked to leukaemia Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from sideeffects associated with that investigational product Administration of LDAC is clinically contraindicated Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL) Patients with blast crisis of chronic myeloid leukaemia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Acute Myeloid Leukaemia,</keyword>
	<keyword>AML</keyword>
</DOC>